Answers are grounded in this paper and cite their sources.
Multicenter study examines prophylaxis effectiveness in reducing organ failure and relapse in congenital thrombotic thrombocytopenic purpura patients, suggesting new treatment pathways.
Congenital thrombotic thrombocytopenic purpura (cTTP) is caused by a severe inherited ADAMTS13 deficiency. While acute episodes are life-threatening, long-term burden of ischemic complications and effectiveness of prophylactic strategies remain underexplored. We conducted a 25-year national, multicenter study of 88 cTTP patients enrolled in the French Thrombotic Microangiopathy (TMA) registry. Patients were stratified by age and clinical context at disease onset: pediatric-onset (n=42), pregnancy-onset (n=33), adult-onset (n=13). Clinical features, genotypes, treatment regimens, and long-term ischemic outcomes were analyzed. Pediatric patients exhibited early-onset disease (median age at diagnosis: 2 years [IQR: 0;13]) with recurrent episodes and a high burden of neurological complications. In patients with pregnancy-onset disease, no relapses were observed outside pregnancy. Adult-onset patients, typically diagnosed >50-year-old, showed prevalent cardiovascular disease, stroke, and kidney injury. Mental health disorders were common across all groups. Despite long-term plasma prophylaxis, organ dysfunction persisted, particularly in pediatric- and adult-onset groups. In pregnancy-onset cTTP, tailored mid-term prophylaxis during pregnancy reduced maternal and fetal complications. Thirty-nine patients received recombinant human ADAMTS13 (rhADAMTS13) prophylaxis (median follow-up: 5 [6-17] months). Prophylactic treatment significantly improved relapse-free survival, with a comparable outcome using intensive plasma-derived products and rhADAMTS13 in pediatric-onset cases, although adverse events were more prevalent using plasmatherapy. Our findings highlight the clinical and genetic heterogeneity of cTTP and the burden of organ dysfunction. Intensive prophylaxis improves relapse-free survival. rhADAMTS13, by reducing the burden of care, represents a safe and promising first-line option that should help reducing long-term organ damage and improving quality of life.
No takes yet. Share an insight, caveat, or question.
Joly et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: